Retatrutide_Dosage, benefits & legal status

Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Trial result: 28.3% (stayed on treatment) · 25.0% (everyone randomised). The first figure describes people who stayed on treatment and the second counts everyone who started. Our write-up of the published trial explains why both figures exist.

Read what dehydration on it actually feels like and when to get help.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

• Retatrutide prices
• Retatrutide vs TirzepatideRetatrutide's 28.3 percent is being set against tirzepatide's 22.5 percent. Different trials, different lengths, and no trial yet comparing the two directly.
• Why Am I So Dehydrated on Retatrutide?Why eating less can leave you short of fluid, the warning signs to watch for, and what the approved GLP-1 labels say about kidney risk.
• Retatrutide Skin Sensitivity: Is It Normal?Dysesthesia hit 12.5% at 12 mg against 0.9% on placebo in the published phase 3 trial, and 20.9% in the knee trial. Why your skin looks normal, and what to say.
• Does Retatrutide Make You Not Care About Anything?Nobody knows, and that means something different here. The mechanism is real, the weight loss is a competing explanation, and no surveillance data exists.
• When Will Retatrutide Be FDA Approved?Lilly named the filing window in an SEC filing. Filing is not approval, the trials are done, and a prescription is realistically 2028 rather than next year.
• Is It Safe to Buy Retatrutide Online?What independent tests of online retatrutide found, how careful buyers check a vial, what it costs and where the law stands.
• Has Anyone Died From Retatrutide? What the Two FDA Reports Actually SayTwo unverified FDA reports describe deaths after people used products sold as retatrutide. Nobody has established what was in the vials, and the controlled trials show no cardiac excess.
• A Counterfeit Retatrutide Vial Put a Patient in the hospital. The Test Record Shows Where the Risk SitsAustralia's regulator traced a torn oesophagus to a vial that contained semaglutide, not retatrutide. Nearly 4,000 blind tests of online vials say the failures cluster in one channel.
• Retatrutide + cagrilintide: untested swapCagriSema is the one stack tested properly, and it ran the two compounds roughly even. This blend runs 83 to 17, with a different GLP-1.
• Retatrutide + tesamorelin: the overlapTesamorelin is added for visceral fat, which retatrutide already reduces substantially. A liver fat substudy found retatrutide cutting it by over 80%.
• Retatrutide + AOD-9604: one failed in 2007AOD-9604 missed its primary endpoint at every dose in a 536-person trial and development was abandoned. Retatrutide has five positive Phase 3 trials.
• Retatrutide + MOTS-c + TesamorelinThree compounds at three stages of proof, pushing blood sugar in three directions. Only one of them carries the evidence on this page.
• Tirzepatide + retatrutide: the label says noSold premixed in one vial. The FDA label for tirzepatide says not to combine it with any GLP-1 receptor agonist, and retatrutide is one.
• Retatrutide + SLU-PP-332: zero and fiveOne half has five Phase 3 trials. The other has no human trial of any kind and is not a peptide. Anti-doping labs are already building tests for it.
• Retatrutide + GHK-Cu: loose skinPeople add GHK-Cu because they are losing weight fast and worried about loose skin. No trial has tested the pair, and the structural problem is elastin.